Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.64 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.64 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.64 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.64 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.64 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.64 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.53 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312815 | 1.00 | HTR1A (0.64) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL989581 | 0.96 | HTR1A (0.69) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL7733796 | 0.87 | HTR1A (0.57) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL7612682 | 0.86 | HTR1A (0.56) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL7736577 | 0.86 | HTR1A (0.54) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL7611697 | 0.86 | HTR1A (0.54) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL6933222 | 0.85 | HTR1A (0.78) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL7610160 | 0.85 | HTR1A (0.67) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL7607814 | 0.84 | HTR1A (0.54) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL6936795 | 0.83 | HTR1A (0.66) | HTR1AADRA1ADRD4ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165025-A1 | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists | RECORDATI IRELAND LTD. (IE) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165025-A1 | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists | HTR1B, HTR1A, HTR2B | HTR1A 2/4885ADRA1A 32/4885DRD4 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.